{"contentid": 488062, "importid": NaN, "name": "FTC and other regulators set out new approach to pharma M&A", "introduction": "The US Federal Trade Commission (FTC) and its counterpart competition enforcement agencies in the USA, European Union, the UK and Canada, are launching a working group to update their approach to analyzing the effects of pharmaceutical mergers.", "content": "<p>The US Federal Trade Commission (FTC) and its counterpart competition enforcement agencies in the USA, European Union, the UK and Canada, are launching a working group to update their approach to analyzing the effects of pharmaceutical mergers.</p>\n<p>Initiated by the FTC, the working group will include the Canadian Competition Bureau, the European Commission Directorate General for Competition, the UK&rsquo;s Competition and Markets Authority, the US Department of Justice Antitrust Division, and Offices of State Attorneys General.</p>\n<p>This joint project taps expertise from competition authorities with whom the FTC cooperates frequently, as well as others with relevant experience, to ensure the most effective enforcement in these crucial markets. The goal of this initiative is to identify concrete and actionable steps to review and update the analysis of pharmaceutical mergers. This project will ensure that FTC investigations include fresh approaches that fully analyze and address the varied competitive concerns that these mergers and acquisitions raise.</p>\n<p>&ldquo;Given the high volume of pharmaceutical mergers in recent years, amid skyrocketing drug prices and ongoing concerns about anticompetitive conduct in the industry, it is imperative that we rethink our approach toward pharmaceutical merger review,&rdquo; said FTC Acting Chairperson Rebecca Kelly Slaughter. &ldquo;Working hand in hand with international and domestic enforcement partners, we intend to take an aggressive approach to tackling anticompetitive pharmaceutical mergers,&rdquo; she noted.</p>\n<h2><strong>Among the questions to be considered:</strong></h2>\n<ul>\n<li>How can current theories of harm be expanded and refreshed?</li>\n<li>What is the full range of a pharmaceutical merger&rsquo;s effects on innovation?</li>\n<li>In merger review, how should we consider pharmaceutical conduct such as price fixing, reverse payments, and other regulatory abuses?</li>\n<li>What evidence would be needed to challenge a transaction based on any new or expanded theories of harm?</li>\n<li>What types of remedies would work in the cases to which those theories are applied?</li>\n<li>What have we learned about the scope of assets and characteristics of firms that make successful divestiture buyers?</li>\n</ul>", "date": "2021-03-17 10:40:00", "meta_title": "FTC and other regulators set out new approach to pharma M&A", "meta_keywords": "Federal Trade Commission, FTC, M&A, Competition, Enforcement, Enforcement, European Commission, CMA", "meta_description": "FTC and other regulators set out new approach to pharma M&A", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-17 10:39:18", "updated": "2021-03-17 10:48:45", "access": NaN, "url": "https://www.thepharmaletter.com/article/ftc-and-other-regulators-set-out-new-approach-to-pharma-m-a", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "federal_trade_commission_big.png", "image2id": "federal_trade_commission_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Competition law, Federal Trade Commission", "sector_tag": "Pharmaceutical", "therapy area_tag": "All therapy areas", "topic_tag": "Companies, mergers and acquisitions, Focus On, Regulation", "geography_tag": "Canada, Europe, UK, USA", "company_tag": "CMA", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-17 10:40:00"}